• Positive FDA feedback supports Phase 2b trial of amsulostat in myelofibrosis
• $8.0 million institutional placement extends cash runway to Q3 2027
• Preliminary SNT-4728 results show reduced inflammation in Parkinson's-related brain region
• SNT-9465 Phase 1b hypertrophic scar trial reaches 60% recruitment
• AZALOX MDS study advances to final Phase 1b dose cohort

Syntara Limited, a clinical-stage drug development company, reported significant progress across its pipeline and financials for the quarter ended 30 June 2026. The company received positive feedback from the US FDA for its proposed Phase 2b trial of amsulostat in myelofibrosis, setting a clear pathway for late-stage clinical development. Additionally, Syntara completed an $8 million institutional placement, strengthening its balance sheet and extending its cash runway into Q3 2027. Preliminary results from the Phase 2 trial of SNT-4728 in isolated REM Sleep Behaviour Disorder (iRBD) showed a statistically significant reduction in inflammation in a key Parkinson's disease-related brain region. The Phase 1b trial of SNT-9465 in hypertrophic scars reached 60% recruitment, with completion targeted for Q3 2026. The AZALOX myelodysplastic syndrome study advanced to the final Phase 1b dose cohort. Syntara expects multiple clinical catalysts in H2 2026, including complete SNT-4728 data, amsulostat MDS interim results, and SNT-9465 top-line results.